Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13928511 | 1.00 | MDM2 (0.47) | MDM2ALDH1A1ALOX15CAPN1NPC1 | |
| SCHEMBL30431821 | 0.90 | MDM2 (0.49) | MDM2PTPN1MEN1KMT2AMDM4 | |
| SCHEMBL19296186 | 0.89 | MDM2 (0.43) | MDM2PTPN1KMT2AMDM4TP53 | |
| SCHEMBL20597255 | 0.89 | MDM2 (0.43) | MDM2PTPN1KMT2AMDM4TP53 | |
| SCHEMBL13342847 | 0.88 | CAPN1 (0.38) | MDM2ALDH1A1ALOX15CAPN1NPC1 | |
| SCHEMBL3266274 | 0.88 | CAPN1 (0.38) | MDM2ALDH1A1ALOX15CAPN1NPC1 | |
| SCHEMBL38666359 | 0.87 | MDM2 (0.53) | MDM2ALDH1A1ALOX15MEN1KMT2A | |
| SCHEMBL2251221 | 0.86 | MDM2 (0.46) | MDM2PTPN1KMT2AMDM4TP53 | |
| SCHEMBL8106707 | 0.82 | MDM2 (0.54) | MDM2PTPN1KMT2AMDM4TP53 | |
| SCHEMBL12052763 | 0.82 | MDM2 (0.54) | MDM2PTPN1KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858387-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seagen Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2020-11-05 | — | — | US | disclosed |
| US-10808039-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190338045-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2019-11-07 | — | — | US | disclosed |
| US-10414826-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| EP-3434275-A1 | ASSAY FOR CANCER CELLS BASED ON THE USE OF AURISTATIN CONJUGATES WITH ANTIBODIES | Seattle Genetics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180127512-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEAGEN INC. | 2018-05-10 | — | — | US | disclosed |
| EP-3120861-A1 | INTERMEDIATE FOR CONJUGATE PREPARATION COMPRISING AURISTATIN DERIVATIVES AND A LINKER | Seattle Genetics, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20160256563-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-7745394-B2 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7498298-B2 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080248053-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080248051-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | SEATTLE GENETICS, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| CN-1938046-A | Monomethylvaline compounds capable of coupling to ligands | SEATTLE GENETICS INC (US) | 2007-03-28 | — | — | CN | disclosed |
| EP-1725249-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seattle Genetics, Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256563-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | CD2BP2, IGSF11, EPB41L2 | MDM2 2907/4885ALDH1A1 994/4885ALOX15 4564/4885 |
| US-20180127512-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | MDM2 1786/4885ALDH1A1 3456/4885ALOX15 3567/4885 |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | MMAB, CAD, TRIM59 | MDM2 2767/4885ALDH1A1 3543/4885ALOX15 2501/4885 |
| US-20080248053-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | MDM2 3113/4885ALDH1A1 3798/4885ALOX15 3050/4885 |
| US-20190338045-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | MDM2 1786/4885ALDH1A1 3456/4885ALOX15 3567/4885 |
| US-10414826-B2 | Monomethylvaline compounds capable of conjugation to ligands | MMAB, CAD, VIM | MDM2 1786/4885ALDH1A1 3456/4885ALOX15 3567/4885 |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | CAD, MMAB, AURKC | MDM2 4027/4885ALDH1A1 4361/4885ALOX15 2393/4885 |
| US-10808039-B2 | Monomethylvaline compounds capable of conjugation to ligands | MMAB, CAD, VIM | MDM2 1786/4885ALDH1A1 3456/4885ALOX15 3567/4885 |
| US-20080226657-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | MDM2 3113/4885ALDH1A1 3798/4885ALOX15 3050/4885 |
| US-20080248051-A1 | Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases | MMAB, CAD, VIM | MDM2 3113/4885ALDH1A1 3798/4885ALOX15 3050/4885 |
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | MDM2 1786/4885ALDH1A1 3456/4885ALOX15 3567/4885 |
| US-20200347149-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | MDM2 1786/4885ALDH1A1 3456/4885ALOX15 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.